抗抑郁药治疗与脑连接性的关联:两项双盲安慰剂对照临床试验的治疗机制研究
两项双盲安慰剂对照试验分别使用度洛西汀和去甲文拉法辛治疗持续性抑郁障碍成人患者,治疗前后进行MRI扫描。结果显示抗抑郁药在丘脑-皮层-中脑导水管周围网络中降低了功能连接,且该连接降低与抑郁症状改善相关。提示该疼痛相关网络可能是新型抗抑郁治疗的重要靶点。
要点
- 抗抑郁药在丘脑-皮层-中脑导水管周围网络中降低功能连接,与安慰剂相比有显著差异。
- 该网络功能连接降低与抑郁症状严重程度改善相关,在两项研究中均得到重复。
- 去甲文拉法辛研究中该网络连接降低还与疼痛症状改善相关。
核心结论
- 与疼痛体验相关的丘脑-皮层-中脑导水管周围网络可能是新型抗抑郁治疗的重要靶点。
研究设计与样本
- 受试者为成人持续性抑郁障碍患者,治疗前后进行MRI扫描,度洛西汀组32例、去甲文拉法辛组34例完成前后扫描。
- 调整性别和年龄后分析全脑功能连接,并检验功能连接变化与24项汉密尔顿抑郁量表及症状自评量表-90修订版疼痛症状改善的相关性。
临床怎么用
- 丘脑-皮层-中脑导水管周围网络的功能连接可作为抗抑郁治疗机制研究和新型药物开发的潜在靶点。
- 临床可关注抗抑郁治疗中该网络连接变化与抑郁及疼痛症状改善的关联,但尚不能作为常规生物标志物使用。
局限性
- 原文未报告样本量之外的局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antidepressant medications offer an effective treatment for depression, yet nearly 50% of patients either do not respond or have side-effects rendering them unable to continue the course of treatment. Mechanistic studies might help advance the pharmacology of depression by identifying pathways through which treatments exert their effects. Toward this goal, we aimed to identify the effects of antidepressant treatment on neural connectivity, the relationship with symptom improvement, and to test whether these effects were reproducible across two studies. METHODS: We completed two double-blind, placebo-controlled trials of SNRI antidepressant medications with MRI scans obtained before and after treatment. One was a 10-week trial of duloxetine (30-120 mg daily; mean 92·1 mg/day [SD 30·00]) and the other was a 12-week trial of desvenlafaxine (50-100 mg daily; 93·6 mg/day [16·47]). Participants consisted of adults with persistent depressive disorder. Adjusting for sex and age, we examined the effect of treatment on whole-brain functional connectivity. We also examined correlations between change in functional connectivity and improvement in symptoms of depression (24-item Hamilton Depression Rating Scale) and pain symptom severity (Symptom Checklist-90-Revised). FINDINGS: Participants were enrolled between Jan 26, 2006, and Nov 22, 2011, for the duloxetine RCT and Aug 5, 2012, and Jan 28, 2016, for the desvenlafaxine RCT. Before and after treatment MRI scans were collected in 32 participants for the duloxetine RCT and 34 participants for the desvenlafaxine RCT. In both studies, antidepressants decreased functional connectivity compared with placebo (duloxetine study: β=-0·06; 95% CI -0·08 to -0·03; p<0·0001, ηp2=0·44; desvenlafaxine study: -0·06, -0·09 to -0·03; p<0·0001, ηp2=0·35) within a thalamo-cortico-periaqueductal network that has previously been associated with the experience of pain. Within the active drug groups, reductions in functional connectivity within this network correlated with improvements in depressive symptom severity in both studies (duloxetine study: r=0·38, 95% CI 0·01-0·65; p=0·0426; desvenlafaxine study: 0·44, 0·10-0·69; p=0·0138) and pain symptoms in the desvenlafaxine study (0·39, 0·04 to 0·65; p=0·0299). INTERPRETATION: The findings suggest the thalamo-cortico-periaqueductal network associated with the experience of pain is a new and potentially important target for novel antidepressant therapeutics. FUNDING: National Mental Health Institute, Eli Lilly and Company, Pfizer Pharmaceuticals, and the Edwin S Webster Foundation.
引用
- Wang Y, Bernanke J, Peterson BS, et al. The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study. Lancet Psychiatry. 2019. PMID: 31248841. doi:10.1016/S2215-0366(19)30179-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。